Key result
LMNA missense mutations exhibit wide phenotypic variability, with variants like p.Arg216Cys expressing less mutant lamin (30:70 mut/wt) and showing a more favorable clinical trajectory.
Answers are grounded in this paper and cite their sources.
The editorial highlights the increasing recognition of phenotypic variability in LMNA missense mutations and emphasizes the need for functional studies and personalized management to predict clinical expression and outcomes.
This article refers to 'The clinical outcome of LMNA missense mutations can be associated with the amount of mutated protein in the nuclear envelope' by R.A. Al-Saaidi et al., published in this issue on pages 1404–1412. Mutations involving the LMNA gene have been linked to a particularly nefarious form of dilated cardiomyopathy (DCM) associated with a high risk of sudden cardiac death (SCD).1, 2 Latterly we are discovering that clinical outcomes are less adverse in carriers of certain LMNA mutations such as the (LMNA-p.Arg216Cys) mutation identified by Al-Saaidi et al.2 in a large family characterized by later onset and more favourable clinical trajectory. The phenotype in the LMNA-p.Arg216Cys pedigree is enriched with cardiac conduction disease (CCD) early on, but DCM and malignant ventricular arrhythmias are less conspicuous, and age of onset later. Similar to the above large family with LMNA-p.Arg216Cys, the recently reported Dutch founder LMNA c.992G > A, p.Arg331Gln mutation is associated with a phenotype reminiscent of other LMNA mutations, but with a more benign course characterized by a better outcome for the composite endpoint of malignant ventricular arrhythmias, end-stage heart failure, or death.3 The heterogeneity of cardiac phenotypes and related risk is increasingly apparent in carriers of LMNA mutations. Factors that may contribute to the interpretation of the pathogenicity of the mutation, mode and age of onset, arrhythmogenic potential and related risk stratification, and left ventricular dysfunction are still largely unknown, also because the clinical manifestations may appear similar but are characterized by a wide individual variability even within families and in carriers of the same mutations (Figure 1). Clinicians need to know more about each individual LMNA mutation, both pathogenicity and malignancy, including genetic data in the list of factors that may contribute to prognostic stratification. To date, the guidelines for primary prevention of SCD in cardiolaminopathies include only non-missense mutations.4 The type of mutation (truncation-predicting/non-missense mutation vs. missense mutation) is one of the factors that are confirmed in many clinical series to be associated with the potential severity of the cardiac phenotype. Non-missense mutations (ins-del/truncating, or mutations affecting splicing) are a risk factor for malignant ventricular arrhythmias5, 6 and early onset of cardiac manifestations,7 including children.8 This effect is also confirmed by clinical studies in large families.9 However, most mutations in LMNA are missense. Many of them are validated in large clinical series and are associated with recurrently similar phenotypes (p.Glu161Lys, p.Arg190Trp, p.Glu317Lys) (http://www.umd.be/LMNA/) characterized by CCD, arrhythmias, left ventricular dysfunction and progressive evolution to end-stage heart failure requiring transplantation.5-10 Recurrent mutations, however, are a minority of all missense mutations in LMNA gene.1 Many of them are private for individual families. The interpretation of their pathogenic role and their clinical effects is especially difficult when they are novel, rare and absent (or minimally represented) in large control databases. In these cases, it is necessary to demonstrate that they are pathogenic and cause the observed phenotypes. Clinical family screening and genotype/phenotype segregation studies assess whether the putative mutation is present or absent in the affected/carrier vs. non-affected/non-carrier family members (Figure 1A–1C). However, families may be characterized by a limited number of members available for segregation studies (e.g. the LMNA-p.Arg471Cys and LMNA-p.Arg471His reported by Al-Saaidi et al.2); the index patient (proband) may be the uniquely affected and alive family member (Figure 1D and 1E); patients may have been adopted, or there may be other reasons that limit segregation studies (Figure 1F and 1G). In these cases, genetic testing by itself has a diagnostic confirmatory role only when the proband carries pathogenic and validated mutations (Figure 1E), or when mutations are de novo—a condition that strongly argues in favour of a pathogenic role (Figure 1D). However, de novo mutations that typically recur in progeria—de novo mutation c.1824C > T, p.G608G11—or in heart-sparing congenital myopathies12 are unusual in cardiolaminopathies, which are more frequently familial diseases. The residue introduced by the mutation can have different effects, as verifiable in patients with LMNA mutations that affect the same residue but predict a different amino acid change (e.g. LMNA-p.Arg471Cys and LMNA-p.Arg471His, or p.Arg190Gln and p.Arg190Trp, or p.Arg377Cys vs. p.Arg377His and p.Arg377Leu)—a not so infrequent mutational event in LMNA gene. We count at least 12 such 'replicative' variants in the published cardiac LMNA literature,1 the majority of which address to either the rod (n = 6) or tail (n = 5), with only one reported case involving the head domain.1 It is reasonable to postulate that the 'malignancy' or penetrance of a given mutation may depend on (or be related with) the mutated residue in terms of its impact on protein folding, dimerization, and intermolecular interactions as hinted to above. But what is more puzzling is that even when mutational invariance appears absolute, phenotypic pleiotropy still abounds: for example, the LMNA-p.Arg471Cys was associated with aggressive DCM and SCD,2 but just recently Florwick et al.13 identified the same mutation in three unrelated asymptomatic ExAC cohort participants. Should we be scrutinizing the myocardial fitness landscape of these mutation-positive disease 'escapers' more rigorously to understand the workings of pleiotropy? This takes us naturally onto the evolving paradigm in heart muscle disease, which regards phenotype as dependent not only on the malignancy of the mutated gene and defect, but also on epigenetics, age, toxic factors, pregnancy, gender, inflammation, and a raft of stochastic processes and acquired diseases in operation throughout the life course.14 Studies that explore the impact of mutations on protein expression and function can significantly contribute to the interpretation of their potential effects. Gene expression, in vitro cellular studies (e.g. fibroblasts from mutated patients)15 and in vivo pathologic studies (endomyocardial biopsy, or heart samples from hearts excised at transplantation)16 can provide morpho-functional evidence of damage caused by the mutation (Figure 1). When myocardial samples are unavailable, fibroblasts derived from skin biopsies of mutation carriers are an easy alternative source of cells that can be used to measure the transcripts of the mutated gene14 via quantitative reverse transcriptase polymerase chain reaction (qRT-PCR), mutated and non-mutated protein expression (Western blotting), presence and distribution of the mutated lamin in cell nuclei (immunohistochemistry), and quantitative amount of the mutated lamin using protein mass spectrometry. In the larger family with LMNA-p.Arg216Cys mutation (more favourable phenotype) reported by Al-Saaidi et al.,2 mutated patients expressed less mutant lamin compared to wild-type protein (30:70 mut/wt), whilst carriers of LMNA-p.Arg471Cys and LMNA-p.Arg471His mutations (more adverse phenotypes) expressed considerably more mutant lamin relative to wild-type (50:50 mut/wt). Open questions may remain, such as for example whether LMNA point mutations suffice to explain the observed discrepancy in mut/wt lamin protein levels. Understanding the structure and function of the gene and protein can help to generate hypotheses. For example, the LMNA-p.Arg216Cys mutation is located on exon 4 and affects a residue localized in the central rod domain coiled region 1B fragment. This region is critical for the formation of the α-helical coiled-coil dimer, the basic building block for the construction of lamin filaments. The more adverse phenotype mutations (LMNA-p.Arg471Cys and LMNA-p.Arg471His) are located on exon 8 and affect the same evolutionarily invariant residue in the tail, just distal to the nuclear localization signal (amino acid 417–422) that critically, governs nuclear residency of the protein. A closer look at published LMNA mutations with cardiac predominant phenotype1 informs that in terms of concentration of mutational hotspots, lamin protein domains feature as follows: rod (65%), tail (29%), head (6%); and within the rod: coiled region 2 (45%), coiled region 1B (42%), coiled region 1A (7%), linker 2 (4%) and lastly, linker 1 (2%). It will be for future work to explore whether there is any significant time-dependent shift in these mut/wt lamin protein expression profiles in missense carriers, and specifically, whether transition from wild-type predominant, to mutant-matched profiles heralds the onset of heart failure and/or malignant arrhythmias in such patients. Cardiac conduction disease is one of the red flags of cardiolaminopathies but it can be absent, thus missing a phenotypic trait that contributes to the diagnostic hypothesis. Why some mutations systematically cause DCM CCD and others do not is as yet unclear. The counter proposition is that CCD is the only clinically expressed trait in some cardiolaminopathies, or that the main clinical manifestations are supraventricular arrhythmias with CCD (Figure 1B). In family A described by Al-Saaidi et al.,2 the member III-7 clinically opens with atrioventricular block (AVB) + left bundle branch block aged 62 years at which point he receives a permanent pacemaker but develops atrial fibrillation at 73 years and dies aged 74 from a stroke without ever apparently developing DCM. Family A member IV-6 manifests only AVB and does not develop DCM in the ensuing 5 years; member IV-10, with CCD and atrial fibrillation, presents with limb-girdle muscular dystrophy but not DCM. Family members IV-10, 12, 14, and 15 manifest AVB and atrial arrhythmias but no DCM within >4 years from the diagnosis of AVB. Therefore, if phenotypic expression (DCM present vs. absent), arrhythmic risk (ventricular and supraventricular arrhythmias), and prognostic stratification (evolution to end-stage heart failure and cardiac transplantation) vary so greatly between affected members of the same family, there is a pressing need to understand what is the minimum level of protection we should be giving to patients to address embolic risk (with regard to atrial arrhythmias), or SCD risk (with regard to ventricular tachycardia). For example, case V-9 experiences non-sustained ventricular tachycardia 1 year after the onset of CCD and permanent pacemaker implantation, but has no more ventricular tachycardia in the ensuing 5 years, even though she manifests at 34 years needing radiofrequency ablation from premature ventricular ectopy of right ventricular outflow tract origin. If co-morbidities are added to the underlying cardiomyopathy [e.g. family A: IV-27 sarcoidosis, IV-24 alcohol abuse and ischaemic heart disease (IHD), IV-16 IHD, IV-1 cancer and IHD],2 it transpires that patients with cardiolaminopathy (as well as other genetic cardiomyopathies) do need personalized management to be able to prevent major events and to support each individual patient safely along his/her entire clinical path. Put simply, an identical cause does not necessarily define an identical prognosis. In conclusion, despite noticeable and quasi-concomitant advances in the cardiac and omics fields, our ability to predict whether and when an LMNA mutation carrier will eventually manifest with heart disease remains suboptimal. To precisely forecast clinical expression and outcomes in this disease, probably requires a large enough number of unrelated mutation carriers per variant, and their systematic follow-up over time. Functional studies should be guaranteed to support the interpretation of rare and novel missense mutations, especially when segregation studies in families are not contributory. E.A. is supported by grants RC IRCCS Foundation Policlinico San Matteo and IRCCS Cardiovascular Network, Italian Ministry of Health. G.C. is supported by the National Institute for Health Research Rare Diseases Translational Research Collaboration to study the deep phenotype of lamin heart disease (NIHR RD-TRC, #171603). Z.B. is supported by DETECTIN-HF project (ERA-CVD framework). Conflict of interest: none declared.
No takes yet. Share an insight, caveat, or question.
Captur et al. (2018) conducted an editorial in Cardiolaminopathies. LMNA missense mutations was evaluated. LMNA missense mutations exhibit wide phenotypic variability, with variants like p.Arg216Cys expressing less mutant lamin (30:70 mut/wt) and showing a more favorable clinical trajectory.
Synapse has enriched 10 related papers. Consider them for comparative context: